Yttrium-90 DOTA satoreotide

N/A

Report date: 2025/11/18 17:45:21

NME

Base Information

Drug NameYttrium-90 DOTA satoreotide

Drug Alias Name90Y-SOMther®90Y-OPS-20190Y-satoreotide

ClassificationSmall molecules > Synthetic peptideRadiation-emitting products > Nuclides > Yttrium > 90YSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) +[5]

Mechanisms of ActionSomatostatin receptor 2 antagonists

TargetsSomatostatin receptor 2

Therapy Area/IndicationsNeuroendocrine Tumors

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesOctreoPharm Sciences GmbH

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOctreoPharm Sciences GmbH

Active IndicationsN/A

Inactive IndicationsNeuroendocrine Tumors

Other Information

ATC CodeN/A